AV 101

Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-Cl-KYNA; AV-101; L-4-chlorokynurenine; L-4-CI-KYN

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Artemis Neuroscience
  • Developer National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Epilepsy; Neuropathic pain; Parkinson's disease
  • Research Huntington's disease; Neurological disorders

Most Recent Events

  • 13 Feb 2017 VistaGen plans to initiate a phase IIb trial of AV 101 as adjunctive treatment for Major depressive disorder in USA, in the second quarter of 2017
  • 13 Feb 2017 VistaGen Therapeutics announces intention to obtain Fast Track designation for AV 101 as an adjunctive treatment for Major depressive disorder in the first half of 2017
  • 13 Feb 2017 VistaGen Therapeutics announces intention to submit an IND application to the US FDA in early 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top